Document Detail


Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa.
MedLine Citation:
PMID:  8774986     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to clarify the effect of lansoprazole on basic fibroblast growth factor (bFGF) during the healing of gastric ulcers in comparison with famotidine and rebamipide. Alteration of the localization and concentration of bFGF was examined in gastric mucosa obtained endoscopically from ulcer patients. The bFGF content was estimated by enzyme-linked immunosorbent assay and the localization of bFGF immunoreactivity was determined by indirect immunohistochemical study using monoclonal antibodies. In the lansoprazole-treated cases, the content and the histochemical immunoreactive area of bFGF significantly increased 4 weeks after the treatment, compared with the group treated with rebamipide and the control group. In the famotidine-treated group, the concentration of bFGF significantly increased, compared with the rebamipide-treated group, and not with control. The number of binding sites for [125I]bFGF, as determined by in vitro autoradiography, also significantly increased in the lansoprazole-treated group. Therefore, an increase in bFGF concentration and receptor distribution was shown to be brought about by treatment with lansoprazole.
Authors:
M Nakamura; M Oda; Y Akiba; J Inoue; T Ito; M Tsuchiya; H Ishii
Related Documents :
8365526 - Laparoscopic management of tubal ectopic pregnancy.
12790266 - Effect of methotrexate on male fertility.
679086 - Interstitial pregnancy following ipsilateral salpingo-oophorectomy.
8592316 - Laparoscopic removal of a dermoid cyst in pregnancy. a case report.
8684756 - Second-trimester amniotic fluid or maternal serum interleukin-10 levels and small for g...
17481696 - Particulate matter and carbon monoxide multiple regression models using environmental c...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  21 Suppl 1     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  1995  
Date Detail:
Created Date:  1996-12-04     Completed Date:  1996-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S24-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Tokyo Denryoku Hospital, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Anti-Ulcer Agents / therapeutic use*
Autoradiography
Binding Sites
Biopsy
Enzyme-Linked Immunosorbent Assay
Fibroblast Growth Factor 2 / drug effects,  metabolism*
Gastroscopy
Humans
Omeprazole / analogs & derivatives*,  therapeutic use
Stomach Ulcer / drug therapy*,  metabolism,  pathology
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103107-01-3/Fibroblast Growth Factor 2; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of extracellular matrix in injury to gastric mucosa by indomethacin.
Next Document:  Gastric mucosal cell proliferation and TGF alpha in the healing of peptic ulcers in human subjects.